<DOC>
	<DOCNO>NCT00096980</DOCNO>
	<brief_summary>This study open label , randomize , multicenter study design compare efficacy 12 week subcutaneously administer efalizumab ( monotherapy ) combination therapy ( Efalizumab topical corticosteroid ointment ) subject moderate severe plaque psoriasis candidate systemic therapy . The study also evaluate safety tolerability 30 month continuous efalizumab treatment subject derive benefit initial 12 week treatment .</brief_summary>
	<brief_title>A Study Evaluate Raptiva Combination With Topical Psoriasis Therapies</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed informed consent Diagnosis plaque psoriasis &gt; =6 month A minimum Psoriasis Area Severity Index ( PASI ) score 12.0 screen Plaque psoriasis cover &gt; =10 % total Body Surface Area ( BSA ) In opinion investigator , candidate systemic therapy psoriasis previously treat ( naive systemic treatment ) receive prior systemic therapy psoriasis ( e.g. , PUVA , cyclosporine , corticosteroid , methotrexate , oral retinoids , mycophenolate mofetil [ MMF ] , thioguanine , hydroxyurea , sirolimus , azathioprine , 6 MP , etanercept ) 18 70 year old Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis Clinically significant psoriasis flare 3 month prior enrollment Pregnancy lactation History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection History opportunistic infection ( e.g. , systemic fungal infection , parasite ) Seropositivity hepatitis B C virus Seropositivity human immunodeficiency virus ( HIV ) History active tuberculosis ( TB ) currently undergo treatment TB Presence history malignancy within past 5 year , include lymphoproliferative disorder Diagnosis hepatic cirrhosis , regardless cause severity Hospital admission cardiovascular pulmonary disease within last year History substance abuse within last 5 year History severe allergic anaphylactic reaction monoclonal antibody fusion protein , contain immunoglobulin ( Ig ) Fc region ( e.g. , etanercept , LFA3TIP ) History severe allergic reaction intolerance topical corticosteroid therapy Previous treatment efalizumab History treatment lymphocytedepleting monoclonal antibody immunoadhesion molecule ( e.g. , antiCD4 , CTLA4Ig , LFA3TIP ) WBC count &lt; 4000/uL &gt; 14,000/uL Hepatic enzyme &gt; =3 time upper limit normal Creatinine &gt; =2 time upper limit normal Any medical condition , judgment investigator , would jeopardize subject 's safety follow exposure study drug Any medical condition , judgment investigator , would significantly interfere subject 's ability comply provision protocol Topical therapy psoriasis Systemic therapy psoriasis Systemic immunosuppressive drug Tanning bed , booth , home UV light source Live virus bacteria vaccine Other vaccine allergy desensitization injection Other experimental drug treatment Nonsteroidal anti inflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>